Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Bifeng Ding
Drug-Drug Interactions Between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir With or Without Dasabuvir
Antimicrobial Agents and Chemotherapy
Infectious Diseases
Pharmacology
Related publications
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for Chronic HCV Infection in US Veterans With Psychiatric Disorders
Journal of Medical Virology
Virology
Infectious Diseases
Safety of Ombitasvir/Paritaprevir/Ritonavir+dasabuvir in Chronic Hepatitis C Patients With HCV Genotype 1 Infection
Acta Poloniae Pharmaceutica
Pharmacology
Pharmaceutical Science
Real-World Experience With Ombitasvir/Paritaprevir Boosted With Ritonavir and Possibly Combined With Dasabuvir and Ribavirin in HCV Infection
Clinical and Experimental Hepatology
Hepatology
Profile of Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir in the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
Time to Viral Suppression Is Not Related to Achievement of SVR12 in HCV GT1-infected Patients Treated With Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin
Journal of Viral Hepatitis
Virology
Hepatology
Infectious Diseases
Effect of Co-Medications on Paritaprevir, Ritonavir, Ombitasvir, Dasabuvir and Ribavirin Pharmacokinetics: Analysis of Data From Seven Phase II/III Trials
Antiviral Therapy
Infectious Diseases
Pharmacology
A Real-Life Data on the Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir +Ribavirin in Patients With Genotype 1 Chronic Hepatitis C Virus Infection in Serbia
Vojnosanitetski Pregled
Medicine
Pharmacology
Stability-Indicating RP-HPLC Method for Simultaneous Quantification of Ombitasvir, Paritaprevir and Ritonavir in Tablet Dosage Form
Asian Journal of Chemistry
Chemistry
Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin for 24 Weeks in Patients With HCV GT4 and Compensated Cirrhosis (AGATE-I Part II)
Health Science Reports
